ContraVir Pharmaceuticals, Inc.
(NASDAQ : CTRV)

( )
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield

Message Boards

...

News

...
Health Technology » Pharmaceuticals Other

Company Profile

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. The company's two of antiviral candidates for treating hepatitis B include phase 2a clinical candidate TXL, a novel, potent analog of the antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a structure that increases its potency and selective index against hepatitis B virus. ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.